Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.
Journal
Cardiology research and practice
ISSN: 2090-8016
Titre abrégé: Cardiol Res Pract
Pays: United States
ID NLM: 101516542
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
10
2022
revised:
03
01
2023
accepted:
26
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes. We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment. We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (
Sections du résumé
Background
UNASSIGNED
Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.
Objectives
UNASSIGNED
To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.
Methods
UNASSIGNED
We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.
Results
UNASSIGNED
We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (
Identifiants
pubmed: 37361000
doi: 10.1155/2023/3197512
pmc: PMC10289876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3197512Informations de copyright
Copyright © 2023 Troels Thim et al.
Déclaration de conflit d'intérêts
Steen Dalby Kristensen has received fees from Idorsia for National Coordinator work. Erik Lerkevang Grove has received speaker honoraria or consultancy fees from Alexion Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, MSD, MundiPharma, Portola Pharmaceuticals, and Lundbeck Pharma. He is an investigator in studies sponsored by AstraZeneca and has received unrestricted research grants from Boehringer Ingelheim. All other authors declare that they have no conflicts of interest.
Références
N Engl J Med. 2009 Dec 10;361(24):2330-41
pubmed: 19915222
Eur Heart J. 2018 Jun 14;39(23):2192-2207
pubmed: 29897428
Clin Epidemiol. 2010 Aug 09;2:137-44
pubmed: 20865111
N Engl J Med. 2013 Apr 4;368(14):1303-13
pubmed: 23473369
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):151-157
pubmed: 30698669
J Clin Pharmacol. 2010 Jan;50(1):27-35
pubmed: 19779037
EuroIntervention. 2021 Dec 03;17(11):e898-e909
pubmed: 34105513
N Engl J Med. 2009 Dec 10;361(24):2318-29
pubmed: 19915221
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
JAMA. 2012 Jan 18;307(3):265-74
pubmed: 22253393